In addition to MEK inhibitors, a recent study revealed that a covalent KRAS inhibitor could inhibit tumor cell growth in NSCLC with KRAS G12C mutation [24, 25], but not in CRC [26]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.